TOMOYA NAKAMURA

Dr. TOMOYA NAKAMURA

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2012 in Diabetes
Verified
Journal Article
Open access
PDF file
YWYasuharu Watanabe
Yasuharu Watanabe
TNTOMOYA NAKAMURA
TOMOYA NAKAMURA
SISho Ishikawa
Sho Ishikawa
SFShiho Fujisaka
Shiho Fujisaka
IUIsao Usui
Isao Usui
YNYoshinori Nagai
Yoshinori Nagai
Recent accumulating evidence suggests that innate immunity is associated with obesity-induced chronic inflammation and metabolic disorders. Here, we show that a Toll-like receptor (TLR) protein, radioprotective 105 (RP105)/myeloid differentiation protein (MD)-1 complex, contributes to high-fat diet (HFD)-induced obesity, adipose tissue inflammation, and insulin resistance. An HFD dramatically increased RP105 mRNA and protein expression in stromal vascular fraction of epididymal white adipose tissue (eWAT) in wild-type (WT) mice. RP105 mRNA expression also was significantly increased in the visceral adipose tissue of obese human subjects relative to nonobese subjects. The RP105/MD-1 complex was expressed by most adipose tissue macrophages (ATMs). An HFD increased RP105/MD-1 expression on the M1 subset of ATMs that accumulate in eWAT. Macrophages also acquired this characteristic in coculture with 3T3-L1 adipocytes. RP105 knockout (KO) and MD-1 KO mice had less HFD-induced adipose tissue inflammation, hepatic steatosis, and insulin resistance compared with wild-type (WT) and TLR4 KO mice. Finally, the saturated fatty acids, palmitic and stearic acids, are endogenous ligands for TLR4, but they did not activate RP105/MD-1. Thus, the RP105/MD-1 complex is a major mediator of adipose tissue inflammation independent of TLR4 signaling and may represent a novel therapeutic target for obesity-associated metabolic disorders.

1 December 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TNTOMOYA NAKAMURA
TOMOYA NAKAMURA
NYNaoki Yoshida
Naoki Yoshida
YYYu Yamanoi
Yu Yamanoi
AHAkira Honryo
Akira Honryo
HTHiroyuki Tomita
Hiroyuki Tomita
YKYoshihiko Kojima
Yoshihiko Kojima
Eucalyptus oil has been used since ancient times for its bactericidal, anti-inflammatory, analgesic and sedative effects. In recent years, the action of Eucalyptus oil has been scientifically proven, and there have been reports that Eucalyptus oil suppresses the production of chemokines, cytokines and lipid mediators in basophils, alveolar macrophages and monocytes. Based on this information, we aimed to verify whether Eucalyptus oil can be used for allergic dermatitis, the incidence of which has been increasing among human skin diseases. This effect was verified using a mouse IgE-mediated local allergic model. In conclusion, topical application of Eucalyptus oil suppressed oedema and vascular permeability enhancement due to IgE-mediated allergic on the skin. In addition, we also verified the degranuration of mast cells, which is a part of its action, and examined whether 1,8-cineole, which is the main component of Eucalyptus oil, suppresses the phosphorylation of PLCγ and p38 directly or indirectly. 1,8-cineole was found to suppress degranulation of mast cells.

1 May 2012 in Journal of Dermatological Science
Verified
Journal Article
Closed access
TNTOMOYA NAKAMURA
TOMOYA NAKAMURA
ANAkiko Nishibu
Akiko Nishibu
MYMitsue Yasoshima
Mitsue Yasoshima
CTChiaki Tanoue
Chiaki Tanoue
NYNaoki Yoshida
Naoki Yoshida
KOKazuo Ogawa
Kazuo Ogawa

26 April 2016 in Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
TNTOMOYA NAKAMURA
TOMOYA NAKAMURA
ANAkiko Nishibu
Akiko Nishibu
NYNaoki Yoshida
Naoki Yoshida
MYMitsue Yasoshima
Mitsue Yasoshima
KAKazushi Anzawa
Kazushi Anzawa
TMTakashi Mochizuki
Takashi Mochizuki

6 December 2017 in Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
TNTOMOYA NAKAMURA
TOMOYA NAKAMURA
NYNaoki Yoshida
Naoki Yoshida
MYMitsue Yasoshima
Mitsue Yasoshima
YKYoshihiko Kojima
Yoshihiko Kojima

6 September 2018 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
TNTOMOYA NAKAMURA
TOMOYA NAKAMURA
NYN. Yoshida
N. Yoshida
KAK. Anzawa
K. Anzawa
ANA. Nishibu
A. Nishibu
TMT. Mochizuki
T. Mochizuki